1 Iodine-125-
12-[m-iodophenyl]-dodecylphosphocholine (NM-3
2 R was measured by using urinary clearance of
iodine 125 ((
125)I) iothalamate.
3 Iodine 125 ((
125)I)-labeled FIAU was used in vitro and i
4 Iodine 125 ((
125)I)-labeled fibrin microparticles inject
5 1 immobilized on Sepharose beads and soluble
iodine 125 ((
125)I)-labeled fibrinogen demonstrated no s
6 F immobilized on Sepharose beads and soluble
iodine 125 ((
125)I)-labeled fibrinogen demonstrated satu
7 and HER2-targeted indium 111 ((111)In)- and
iodine 125 ((
125)I)-labeled panitumumab and trastuzumab,
8 tic brachytherapy (SBT) with implantation of
iodine-125 ((
125)I) seeds as a safe and effective local
9 -coated surfaces followed by the addition of
iodine 125 (
125I) monoclonal antibodies (mAbs) directed
10 ancer patients were treated with radioactive
iodine 125 (
125I) prostate implants followed by external
11 It was labeled with
iodine-125 (
125I) to trace the concentration of antibody
12 onkey (Macaca mulatta) was assessed by using
iodine 125 ([
125I)-Tyr0]-sauvagine with or without the s
13 n strand cleavage by the Auger radiodecay of
iodine 125,
allows us to determine the distances between
14 Biodistribution studies of the
iodine-125 analogue showed 3% ID/g in LNCaP xenograft tu
15 Iodine-125 and palladium-103 are each reasonable isotope
16 rbidities, type of isotope (ruthenium 106 or
iodine 125),
and initial VA ( >20/50 or <20/50).
17 Intervention was
Iodine 125,
and Palladium 103 plaque brachytherapy.
18 BVM) were synthesized, exchange-labeled with
iodine-125,
and evaluated as possible in vivo markers fo
19 nd-guided TIPPB with either palladium-103 or
iodine-125 as monotherapy or combined with external radi
20 For the
iodine-125 brachytherapy and endoresection groups, respe
21 atients with choroidal melanoma treated with
iodine-125 brachytherapy and intraoperative FNAB from Ja
22 ngle choroidal tumor, which was treated with
iodine-125 brachytherapy and underwent intraoperative fi
23 was performed for 225 patients treated with
iodine-125 brachytherapy for uveal melanoma.
24 ic spread was observed in 11 patients in the
iodine-125 brachytherapy group vs only 1 patient in the
25 al tumor location with 54 cases treated with
iodine-125 brachytherapy.
26 atients treated with either endoresection or
iodine-125 brachytherapy.
27 with outcomes similar to those obtained with
iodine-125 brachytherapy.
28 istorical controls treated with surgery plus
iodine-125 brachytherapy.
29 Plaque radiotherapy with
iodine-125,
cobalt-60, iridium-192, or ruthenium-106.
30 nosed with UM and treated with low-dose-rate
Iodine-125 EPBT between 1984 and 2022.
31 titution's experience of using low-dose-rate
Iodine-125 EPBT for the treatment of UM over a period of
32 Low-dose-rate
Iodine-125 EPBT yields similar complication rates to tho
33 as delivered to prostate only (145 Gy if 125-
Iodine, 125 Gy if 103-Pd).
34 Iodine-125 HPP-forskolin and [3H]cytochalasin B did not
35 Iodine-125 HPP-forskolin and [3H]cytochalasin B did not
36 if a greater tumor regression response after
iodine 125 (
I(125)) brachytherapy correlates with class
37 A total of 1201 patients that underwent
iodine-125 (
I-125) EPBT as primary treatment for PUM bet
38 Iodine-125-
IACFT was prepared in > 60% radiochemical yie
39 d glomerular filtration rate measured by the
iodine-125 iothalamate (Glofil) test and renal biopsy fi
40 Iodine-125-
IUdR was infused intracerebrally over a 2-day
41 ons for selective binding of the radioligand
iodine 125-
labeled (R)-trans-7-hydroxy-2-[N-propyl-N-(3'
42 etermine the maximum-tolerated dose (MTD) of
iodine 125-
labeled monoclonal antibody A33 (125I-mAb A33
43 Biodistribution studies of the
iodine-125-
labeled compounds in MDA-MB-231 mouse xenogra
44 Immunoprecipitation assays with
iodine-125-
labeled epibatidine and solubilized human neu
45 Iodine-125-
MAbs provided quantification of circulating a
46 iary body or choroidal melanoma treated with
iodine 125 or ruthenium 106 episcleral brachytherapy bet
47 diately before implantation of a radioactive
iodine 125 plaque as treatment for the tumor.
48 Low-dose
iodine-125 plaque brachytherapy (67.5-81 Gy at tumor ape
49 Iodine-125 plaque brachytherapy for uveal melanoma carri
50 Transscleral FNAB at the time of
iodine-125 plaque brachytherapy was not associated with
51 Seven years after
iodine-125 plaque brachytherapy, systemic imaging identi
52 /- 14 years; 50.4% female) were treated with
Iodine-125 plaque brachytherapy.
53 Iodine-125 plaque brachytherapy.
54 Custom-designed
iodine-125 plaque radiotherapy delivering planned 8000 c
55 Iodine-125 plaque radiotherapy is effective in the manag
56 Iodine-125 plaque radiotherapy provides adequate tumor c
57 Custom designed
iodine-125 plaque radiotherapy.
58 er surgical resection that were treated with
iodine-125 plaque radiotherapy.
59 ry 1, 1990, through December 30, 2010, using
iodine 125 plaques and treatment simulation software dev
60 Radiolabeled with
iodine-125,
Rho-FF-Van shows strong radioactive signal i
61 selective removal of the clipped node using
iodine-125 seed localization.
62 Iodine-125-
T101 (100 micrograms, 1 ml) was mixed with 90
63 r, (125)I-KX1, we delivered an Auger emitter
iodine-125 to PARP-1: a chromatin-binding enzyme overexp